This article refers to:
Zoellner Y, Balp MM, Gili Marco A. The role of galenic innovation in improving treatment compliance and persistence: three case studies. Clinicoecon Outcomes Res. 2011;3:109–116.
In the results section of the abstract, “…+15% in Germany for desferrioxamine vs deferasirox.” should read “…+15% in Germany for deferasirox vs desferrioxamine.”
In the ‘Compliance’ section, “…and +15% in Germany for desferrioxamine vs deferasirox.” should read “…and +15% in Germany for deferasirox vs desferrioxamine.”